These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19388726)

  • 41. Medicine Safety Monitoring in Pediatric Population in India.
    Kaur I; Kalaiselvan V; Singh GN
    Indian J Pediatr; 2016 May; 83(5):479-80. PubMed ID: 26634262
    [No Abstract]   [Full Text] [Related]  

  • 42. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
    Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
    S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
    Getova VI; Georgiev SR; Stoimenova AH; Petkova-Georgieva ES
    Folia Med (Plovdiv); 2018 Sep; 60(3):447-453. PubMed ID: 30355838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
    Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
    Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Principles of signal detection in pharmacovigilance.
    Meyboom RH; Egberts AC; Edwards IR; Hekster YA; de Koning FH; Gribnau FW
    Drug Saf; 1997 Jun; 16(6):355-65. PubMed ID: 9241490
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
    Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
    Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
    Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
    Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Recording and assessment of medication errors : Experience of the Drug Commission of the German Medical Association].
    Köberle U; Stammschulte T; Gundert-Remy U; Pitzer M; Bräutigam K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1066-1074. PubMed ID: 30022236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The value of case reports in pharmacovigilance.
    Garcia-Doval I; Segovia E; Hunter H; Frew J; Naldi L
    Br J Dermatol; 2020 Nov; 183(5):795-796. PubMed ID: 33135791
    [No Abstract]   [Full Text] [Related]  

  • 52. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
    Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
    Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia.
    Adenuga BA; Kibuule D; Rennie TW
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):247-253. PubMed ID: 31520574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Annual review of pharmacovigilance.
    Diesel G; Cooles S
    Vet Rec; 2018 Jul; 183(2):72. PubMed ID: 30002183
    [No Abstract]   [Full Text] [Related]  

  • 55. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting.
    Dormann H; Muth-Selbach U; Krebs S; Criegee-Rieck M; Tegeder I; Schneider HT; Hahn EG; Levy M; Brune K; Geisslinger G
    Drug Saf; 2000 Feb; 22(2):161-8. PubMed ID: 10672897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
    Baldo P; Francescon S; Fornasier G
    Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
    La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacovigilance in oncology.
    Baldo P; Fornasier G; Ciolfi L; Sartor I; Francescon S
    Int J Clin Pharm; 2018 Aug; 40(4):832-841. PubMed ID: 30069667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Canada's Adverse Drug Reaction Reporting System: A Failing Grade.
    Rawson NS
    J Popul Ther Clin Pharmacol; 2015; 22(2):e167-72. PubMed ID: 26590356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.